Skip to content

Replimune Group REPL Prepaid & Other Current

Prepaid & Other Current at other companies

Amgen logo
AmgenAMGN
$4.11B+26.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$620.9M+32.4%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$9.5M+42.8%
Immunome logo
ImmunomeIMNM
$11.62M+100%
CG Oncology logo
CG OncologyCGON
$23.13M+86.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
$10M-0.4%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's prepaid & other current?
Replimune Group (REPL) reported prepaid & other current of $8.26M in Q4 2025.
How has Replimune Group's prepaid & other current changed year-over-year?
Replimune Group's prepaid & other current increased by 3.6% year-over-year, from $7.97M to $8.26M.
What is the long-term trend for Replimune Group's prepaid & other current?
Over 4 years (2021 to 2025), Replimune Group's prepaid & other current has grown at a 16.8% compound annual growth rate (CAGR), from $4.49M to $8.35M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.